Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings of $0.00 per share from the same period last year. The company reported quarterly sales of $41.000 million which beat the analyst consensus estimate of $23.405 million by 75.17 percent. This is a 74.38 percent decrease over sales of $160.000 million the same period last year.